Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma

Blood

Volumn 124, Issue 13, 2014, Pages 2081-2090

  Hoellein, Alexander ^a   Fallahi, Mohammad ^b   Schoeffmann, Stephanie ^a   Steidle, Sabine ^a   Schaub, Franz X ^b,g   Rudelius, Martina ^c   Laitinen, Iina ^a   Nilsson, Lisa ^d   Goga, Andrei ^e   Peschel, Christian ^a,f   Nilsson, Jonas A ^d   Cleveland, John L ^b,g   Keller, Ulrich ^a,f  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; ANACARDIC ACID; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; B CELL LYMPHOMA; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE EXPRESSION SYSTEM; IMMUNOBLOTTING; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; POLYPLOIDY; PROTEIN PROCESSING; SUMOYLATION; ANIMAL; CELL CYCLE CHECKPOINT; CELL TRANSFORMATION; CLUSTER ANALYSIS; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANACARDIC ACIDS; ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, TRANSGENIC; POLYPLOIDY; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSCRIPTION, GENETIC; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84907273688     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-584524     Document Type: Article

References (61)

1. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20(40):5595-5610.
2. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 2002;84:81-154.
3. Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35.
4. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976-990.
5. Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer Res. 2009;69(23):8839-8843.
6. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8(4):253-267.
7. Martins CP, Berns A. Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J. 2002;21(14):3739-3748.
8. Keller UB, Old JB, Dorsey FC, et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 2007;26(10):2562-2574.
9. Bawa-Khalfe T, Yeh ET. SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer. 2010;1(7):748-752.
10. Yang XJ, Chiang CM. Sumoylation in gene regulation, human disease, and therapeutic action. F1000Prime Rep. 2013;5:45.
11. Wang Y, Dasso M. SUMOylation and deSUMOylation at a glance. J Cell Sci. 2009;122(Pt 23):4249-4252.
12. Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT. A role for Ubc9 in tumorigenesis. Oncogene. 2005;24(16):2677-2683.
13. Moschos SJ, Smith AP, Mandic M, et al. SAGE and antibody array analysis of melanomainfiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene. 2007;26(29):4216-4225.
14. Driscoll JJ, Pelluru D, Lefkimmiatis K, et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010;115(14):2827-2834.
15. Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer. 2010;1(6):650-659.
16. Kaelin WG Jr. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 2009;1(10):99.
17. den Hollander J, Rimpi S, Doherty JR, et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood. 2010;116(9):1498-1505.
18. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci USA. 2010;107(31):13836-13841.
19. Höglund A, Nilsson LM, Muralidharan SV, et al. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res. 2011;17(22):7067-7079.
20. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10(4):301-309.
21. Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008;456(7224):971-975.
22. Chen L, Aktas BH, Wang Y, et al. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget. 2012;3(8):869-881.
23. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci USA. 2013;110(29):11988-11993.
24. Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2012;335(6066):348-353.
25. Pajic A, Spitkovsky D, Christoph B, et al. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000;87(6):787-793.
26. Fellmann C, Zuber J, McJunkin K, et al. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell. 2011;41(6):733-746.
27. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-538.
28. Silva JM, Li MZ, Chang K, et al. Secondgeneration shRNA libraries covering the mouse and human genomes. Nat Genet. 2005;37(11):1281-1288.
29. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005;37(11):1289-1295.
30. Zuber J, McJunkin K, Fellmann C, et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol. 2011;29(1):79-83.
31. Nilsson JA, Keller UB, Baudino TA, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell. 2005;7(5):433-444.
32. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 39-deoxy-39-[F-18]fluorothymidine ([F-18]FLT). J Radioanal Nucl Chem. 2000;243(3):843-846.
33. Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 2010;11(12):861-871.
34. Lovén J, Orlando DA, Sigova AA, et al. Revisiting global gene expression analysis. Cell. 2012;151(3):476-482.
35. Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56-67.
36. Seitz V, Butzhammer P, Hirsch B, et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS ONE. 2011;6(11):e26837.
37. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669.
38. de Alboran IM, O'Hagan RC, Gärtner F, et al. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 2001;14(1):45-55.
39. Heng TS, Painter MW; Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 2008;9(10):1091-1094.
40. Hummel M, Bentink S, Berger H, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419-2430.
41. Fukuda I, Ito A, Hirai G, et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem Biol. 2009;16(2):133-140.
42. Kim YS, Nagy K, Keyser S, Schneekloth JS Jr. An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation. Chem Biol. 2013;20(4):604-613.
43. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell. 1997;88(1):97-107.
44. Furuya M, Tsuji N, Kobayashi D, Watanabe N. Interaction between survivin and aurora-B kinase plays an important role in survivin-mediated up-regulation of human telomerase reverse transcriptase expression. Int J Oncol. 2009;34(4):1061-1068.
45. Dörr JR, Yu Y, Milanovic M, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature. 2013;501(7467):421-425.
46. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 2007;13(7):820-827.
47. Nilsson LM, Keller UB, Yang C, Nilsson JA, Cleveland JL, Roussel MF. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis. Oncogene. 2007;26(20):2833-2839.
48. Keller U, Nilsson JA, Maclean KH, Old JB, Cleveland JL. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene. 2005;24(41):6231-6240.
49. Nilsson JA, Nilsson LM, Keller U, Yokota Y, Boyd K, Cleveland JL. Id2 is dispensable for myc-induced lymphomagenesis. Cancer Res. 2004;64(20):7296-7301.
50. Amente S, Lavadera ML, Palo GD, Majello B. SUMO-activating SAE1 transcription is positively regulated by Myc. Am J Cancer Res. 2012;2(3):330-334.
51. Chappell J, Dalton S. Roles for MYC in the establishment and maintenance of pluripotency. Cold Spring Harb Perspect Med. 2013;3(12):a014381.
52. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell. 2008;2(4):333-344.
53. Sabò A, Doni M, Amati B. SUMOylation of Myc-amily proteins. PLoS ONE. 2014;9(3):e91072.
54. Soucek L, Whitfield JR, Sodir NM, et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013;27(5):504-513.
55. Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452-3459.
56. Bellas C, García D, Vicente Y, et al. Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. PLoS ONE. 2014;9(6):e98169.
57. O'Hagan RC, Ohh M, David G, et al. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 2000;14(17):2185-2191.
58. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011;2(3):209-221.
59. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786(1):60-72.
60. Ferńandez-Miranda G, Pérez de Castro I, Carmena M, et al. SUMOylation modulates the function of Aurora-B kinase. J Cell Sci. 2010;123(Pt 16):2823-2833.
61. Pérez de Castro I, Aguirre-Portolés C, Martin B, et al. A SUMOylation motif in Aurora-A: implications for spindle dynamics and oncogenesis. Front Oncol. 2011;1:50.